Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies

Regulations by 2FIRSTS.ai
Jun.24.2024
Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies
Australia government withdraws e-cigarette sales plan, allowing non-prescription purchase at pharmacies. Health Minister Mark Butler reached agreement with Greens.

According to The Sydney Morning Herald on June 24th, the Australian government has withdrawn its plan to allow e-cigarettes to be sold commercially. E-cigarettes will not require a prescription to be purchased in pharmacies.

 

Minister of Health Mark Butler reached an agreement with the Green Party on Monday, June 24th, to relax the ban on e-cigarettes scheduled to take effect in July. This was in order to pass legislation in the Senate to prohibit retail sales, as the initially stricter proposal did not have the support of the majority of senators.

 

According to sources familiar with the agreement, after the ban on e-cigarettes takes effect in July, consumers will still need a doctor's prescription to purchase e-cigarettes. However, in the future, adults will not need a prescription from a general practitioner to buy e-cigarettes from pharmacies. They will only need to speak with a pharmacist and can purchase them over the counter.

 

At the same time, individuals under the age of 18 are allowed to purchase e-cigarettes with a prescription from a clinician if deemed appropriate.

 

The government has promised to provide additional funding to support young people in quitting e-cigarettes.

 

E-cigarettes sold in pharmacies will still be regulated and must comply with standard packaging requirements.

 

Butler's adjustment is a concession to the substantial political capital invested in the success of the e-cigarette ban. He will announce the full details of the changes later today.

 

Butler previously proposed the idea of allowing people to purchase e-cigarettes from pharmacies without a prescription, but he stated that this would only be considered if the prescription drug model is not successful.

 

He stated in November of last year,

 

Health ministers are interested in exploring whether e-cigarettes can be provided solely by pharmacists in pharmacies, where similar products are often located behind the counter and require interaction with a pharmacist but not a doctor's prescription.

 

We have not made a decision yet, but I have said that if the proposed reform does not adequately ensure that people with genuine treatment needs can access e-cigarettes, we will consider other options.

 

Both the Greens and the National Party have expressed doubt about the proposal put forward by the Labor Party to ban all retail sales of e-cigarettes and require a prescription from a general practitioner to obtain them from a pharmacy. This is a stricter version of the law first proposed by former Coalition Health Minister Greg Hunt in 2021.

 

The Green Party and the two major political parties are aligned in their desire to prevent children from purchasing e-cigarettes from unlicensed stores.

 

However, the Greens' health spokesperson, Jordon Steele-John, expressed concerns about the difficulties and costs of quitting smoking for those who need to make an appointment with a general practitioner in order to get a prescription. The Department of Health's analysis of Butler's original plan indicates that 450,000 Australians per year will seek e-cigarette prescriptions, requiring nearly one million visits to general practitioners.

 

John also expressed skepticism towards the prohibition model, pointing out that drug bans have proven to be ineffective.

 

Many young Australians are using e-cigarettes, banning the sale of e-cigarettes could potentially become a political issue.

 

No one should be punished for personal use of e-cigarettes. Prohibition policies for drugs have failed. Many people under the age of 18 are becoming addicted to nicotine. We need to ensure there are proper resources in place to help these individuals quit using e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Japan's Heated Tobacco Use Rises From 0.1% to 14.9% Over a Decade as Growth Extends Beyond Cigarette Switching
Japan's Heated Tobacco Use Rises From 0.1% to 14.9% Over a Decade as Growth Extends Beyond Cigarette Switching
A decade-long study published in The Lancet Regional Health – Western Pacific found that heated tobacco product use in Japan increased from 0.1% in 2015 to 14.9% in 2025, although growth slowed after 2018. Switching from conventional cigarettes remained an important source of HTP uptake, while the contribution from previously non-current users increased. Approximately 56% of HTP users also smoked conventional cigarettes in 2025. Separate industry data show that Japan's heated tobacco sales reached 73.4 billion units in fiscal 2025, approaching conventional cigarette sales of 78.2 billion units.
SCIENCE
Nov.10
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22